Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > January 2014 - Volume 21 - Issue 1 > Methods for the design of vasomotor symptom trials: the Meno...
Menopause:
doi: 10.1097/GME.0b013e31829337a4
Original Articles

Methods for the design of vasomotor symptom trials: the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network

Newton, Katherine M. PhD1; Carpenter, Janet S. PhD, RN, FAAN2; Guthrie, Katherine A. PhD3; Anderson, Garnet L. PhD3; Caan, Bette DrPH4; Cohen, Lee S. MD5; Ensrud, Kristine E. MD, MPH6; Freeman, Ellen W. PhD7; Joffe, Hadine MD5; Sternfeld, Barbara PhD4; Reed, Susan D. MD, MPH8; Sherman, Sheryl PhD9; Sammel, Mary D. ScD10; Kroenke, Kurt PhD11; Larson, Joseph C. MS3; LaCroix, Andrea Z. PhD3

Collapse Box

Abstract

Objective

This report describes the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network and methodological issues addressed in designing and implementing vasomotor symptom trials.

Methods

Established in response to a National Institutes of Health request for applications, the network was charged with conducting rapid throughput randomized trials of novel and understudied available interventions postulated to alleviate vasomotor and other menopausal symptoms. Included are descriptions of and rationale for criteria used for interventions and study selection, common eligibility and exclusion criteria, common primary and secondary outcome measures, consideration of placebo response, establishment of a biorepository, trial duration, screening and recruitment, statistical methods, and quality control. All trial designs are presented, including the following: (1) a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness of the selective serotonin reuptake inhibitor escitalopram in reducing vasomotor symptom frequency and severity; (2) a two-by-three factorial design trial to test three different interventions (yoga, exercise, and ω-3 supplementation) for the improvement of vasomotor symptom frequency and bother; and (3) a three-arm comparative efficacy trial of the serotonin-norepinephrine reuptake inhibitor venlafaxine and low-dose oral estradiol versus placebo for reducing vasomotor symptom frequency. The network’s structure and governance are also discussed.

Conclusions

The methods used in and the lessons learned from the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health trials are shared to encourage and support the conduct of similar trials and to encourage collaborations with other researchers.

© 2013 by The North American Menopause Society

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.